In overweight/obese patients with impaired fasting glucose or impaired glucose tolerance, n-3 PUFAs reduced glycemia and fasting plasma insulin [186], while in T2DM patients with omega-3 supplementation, a high ratio of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) contributed to a greater decreasing tendency in plasma insulin and HbAc1, although with no statistically significant results [187]. This evidence concerns the gene INS and type 2 diabetes mellitus.